Compare Applied Digital Corporation (APLD) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Applied Digital Corporation vs BridgeBio Pharma Inc — how do they compare? Applied Digital Corporation trades at $29.94 (market cap $8.90B), while BridgeBio Pharma Inc trades at $83.2 (market cap $16.81B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Applied Digital Corporation nearer its low. Which is the better fit depends on your goals.
| APLD | BBIO | |
|---|---|---|
Market Cap | $8.90B | $16.81B |
Sector | Technology | Health |
52-Week High | $49.65 | $90.17 |
52-Week Low | $9.18 | $44.81 |
Enterprise Value | $10.00B | $18.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Digital (APLD) trades at $31.15, down 3.53% today, amid bearish technical signals despite unanimous analyst buy ratings. The company shows strong revenue growth with $144M in 2025 and $319M projected for 2026, but remains unprofitable with negative margins. Recent news highlights APLD's pivot to AI data centers with $36B in contracted lease value, though execution risks and customer concentration persist.
Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and heavy capital spending. Risks include customer concentration and debt load, but analyst consensus targets $76.67 suggest significant upside if execution improves.
BridgeBio Pharma (BBIO) trades at $85.89, down 4.75% today but remains near 52-week highs following positive clinical news. The stock shows strong technical momentum with bullish moving averages and support at $85. Fundamentally, revenue grew to $502M in 2025 but net losses widened to -$725M with negative cash flow from operations. Recent news highlights competitor setbacks boosting confidence in Attruby and a $1B preferred equity raise to fund launches.
Outlook hinges on successful drug launches and pipeline execution, with analyst consensus bullish (92% buy ratings) and a $103 price target. Key risks include sustained cash burn, clinical trial outcomes, and high valuation (P/S 28.5) pricing in future success. The stock offers growth potential but requires monitoring of profitability milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Digital Corporation
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
